A Phase 1 interventional study of Vamifeport Formulation 1 and Vamifeport Formulation 2 in Healthy, sponsored by Vifor (International) Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-17.
Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Two different vamifeport oral formulations will be administered in fed and fasted state to assess the vamifeport food-drug interaction and to assess the relative bioavailability (the proportion of drug entering the circulation) of 2 different vamifeport oral formulations in healthy adult participants.
Participants will be randomly allocated to one of four treatment sequences, with four dosing periods each, where different combinations of both formulations will be administered following fasted and fed state.
The total study duration for each participant is up to 7 weeks and 4 days.
Vifor (International) Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
First submitted before Vifor (International) Inc. became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 1 * Day 5: Participants in fed state receive Vamifeport Formulation 1 * Day 9: Participants in fed state receive Vamifeport Formulation 2 * Day 13: Participants in fasted state receive Vamifeport Formulation 2
Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2
Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 1 * Day 5: Participants in fasted state receive Vamifeport Formulation 2 * Day 9: Participants in fasted state receive Vamifeport Formulation 1 * Day 13: Participants in fed state receive Vamifeport Formulation 2
Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2
Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 2 * Day 5: Participants in fed state receive Vamifeport Formulation 2 * Day 9: Participants in fed state receive Vamifeport Formulation 1 * Day 13: Participants in fasted state receive Vamifeport Formulation 1
Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2
Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 2 * Day 5: Participants in fasted state receive Vamifeport Formulation 1 * Day 9: Participants in fasted state receive Vamifeport Formulation 2 * Day 13: Participants in fed state receive Vamifeport Formulation 1
Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2
Vamifeport Formulation 1 is available as 60 mg oral capsules
Vamifeport Formulation 2 is available as 60 mg oral capsules
Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-last) of vamifeport
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time (AUC0-infinity) of vamifeport
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Maximum observed concentration (Cmax) of vamifeport
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Time of maximum vamifeport plasma concentration (Tmax)
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Apparent terminal disposition phase half-life (tl/2)
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Apparent terminal disposition phase rate constant
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Apparent total clearance
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Apparent volume of distribution during the terminal disposition phase
Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Dec 2021, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.